Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6063636 | 0.82 | NR1H4 (0.51) | MEN1KMT2AABCG2ALDH1A1 | |
| SCHEMBL6063634 | 0.82 | NR1H4 (0.51) | MEN1KMT2AABCG2ALDH1A1 | |
| SCHEMBL6062734 | 0.81 | MAPT (0.47) | AKR1C3CYP3A4MEN1KMT2ATP53 | |
| SCHEMBL6062729 | 0.81 | MAPT (0.47) | AKR1C3CYP3A4MEN1KMT2ATP53 | |
| SCHEMBL8125711 | 0.80 | AKR1C3 (0.41) | AKR1C3AKR1C1CYP3A4CYP2C9MEN1 | |
| SCHEMBL27018581 | 0.79 | AKR1C3 (0.43) | AKR1C3MEN1KMT2AHTTPTGS2 | |
| Hydrogen Sulfide SCHEMBL23215080 | 0.77 | AKR1C1 (0.40) | AKR1C3AKR1C1MEN1KMT2AHTT | |
| SCHEMBL4649014 | 0.77 | AKR1C3 (0.47) | AKR1C3AKR1C1CYP3A4CYP2C9MEN1 | |
| SCHEMBL7153123 | 0.77 | AKR1C3 (0.47) | AKR1C3AKR1C1CYP3A4CYP2C9MEN1 | |
| SCHEMBL4649011 | 0.77 | AKR1C3 (0.47) | AKR1C3AKR1C1CYP3A4CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053071-B2 | For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells | THE BURNHAM INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176506-A1 | Induction of apoptosis in cancer cells | MCL1, BAD, BCL2 | AKR1C3 1995/4885AKR1C1 1994/4885CYP3A4 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.